The energy of immunity powerfully counteracts COVID

Inhalation with Arecur

In 2020, humanity faced a terrible disease - the COVID 19 pandemic. Later, it became known that the disease affects not only the elderly and people with chronic diseases, but also people with reduced immunity. Common consequences of COVID are: pneumosclerosis on the background of inflammation, chronic cough, attacks of suffocation and later - respiratory failure. All these consequences can remain with a person for the rest of his life and in the worst cases - life itself faces an imminent threat. The risk of lung cancer increases, especially in cases when the coronavirus infection causes exacerbations of chronic obstructive pulmonary disease (COPD).


To overcome the terrible consequences of Covid, effective support of respiratory tract immunity system is necessary. Immuno-corrector Arecur® in the form of inhalations provides the respiratory system with the immune energy - and then pneumosclerosis does not occur at the site of inflammation, activated immune cells clean the bronchi from the remains of the infection. Cough subsides and breathing becomes free. Protecting the respiratory tract is important for cancer prevention. Thanks to their properties, formed by an evolution for millions of years, immune peptides are able to reduce inflammation. Conversely, when immunity is needed, peptides activate the necessary number of immune cells to counter the danger effectively.[1] The mechanism of activation of immune cells is quite simple: being accumulated, immune peptides attach to cell membranes on the mucous membrane, and thus provoke their inspection by the patient's own T-lymphocytes.[2] Thus the probability of detecting damaged cells is increased and immunoprophylaxis of bronchial cancer is implemented. Currently, the accumulated clinical data confirm that the use of the anti-relapse immuno-corrector Arecur® in the form of inhalations protects the patients’ respiratory tract from infection and thus prevents possible frequent relapses of COPD.[3]


The use of Arecur® inhalations is most effective according to the preventive scheme, before the SARS season - 1 inhalation per day, a course of 10 inhalations, preventive courses are recommended for patients with COPD at least 2 times a year. If the exacerbation of disease does occur, inhalations are prescribed during the recovery period after the temperature drops. It is recommended to take Arecur® capsules not only during the rehabilitation period after an exacerbation of COPD, but also for the prevention of seasonal viral infections and for the promotion of cellular immunity in effective resistance to pathogens. Take 1 capsule 2 times a day for 1 month in the cold season. Arecur® is fully compatible with antibacterial drugs and anti-inflammatory therapy. 


Immune energy, which is provided to the mucous membranes of the respiratory tract by the immune peptides, creates conditions for effective resistance to possible threats, especially during periods of seasonal colds and generally in the era of the Covid-19 pandemic.

 

Sources
1.Stoliarova O et al.  Study of the Exogenous Peptide Effect on the TGF-β1 Expression-A Risk Factor for the Hepatocellular Carcinoma Recurrence. American Journal of Biomedical and Life Sciences. 2019 – 7(4): 73 – 78.
2.Kurchenko A. et al. Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology. International Journal of Immunology. 2020 – 8(1): 1 – 8.
3.Panashchuk I, Tatskyi O et al. COPD: Perspectives of Immune Peptide Therapy and Lung Cancer Prevention, American Journal of Internal Medicine. 2021 -  9 (6): 248-252.